Search

Search Constraints

You searched for: Author/Creator Flinn, I.

Search Results

11. P649: A FIRST-IN-HUMAN PHASE 1 TRIAL OF NX-2127, A FIRST-IN-CLASS ORAL BTK DEGRADER WITH IMID-LIKE ACTIVITY, IN PATIENTS WITH RELAPSED AND REFRACTORY B-CELL MALIGNANCIES. (23rd June 2022)

12. PATTERNS OF DUVELISIB‐INDUCED LYMPHOCYTOSIS IN PATIENTS WITH R/R CLL OR SLL INCLUDING THOSE WITH HIGH‐RISK FACTORS TREATED IN THE DUO TRIAL. (12th June 2019)

13. POST HOC ANALYSES OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA WHO RECEIVED LENALIDOMIDE PLUS RITUXIMAB (R2) VS RITUXIMAB/PLACEBO (AUGMENT). (12th June 2019)

14. PRELIMINARY RESULTS OF THE PHASE 2 STUDY OF ZANUBRUTINIB IN PATIENTS WITH PREVIOUSLY TREATED B‐CELL MALIGNANCIES INTOLERANT TO IBRUTINIB AND/OR ACALABRUTINIB. (17th June 2021)

15. S147: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED CLL/SLL: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY. (23rd June 2022)

16. S212: PHASE I STUDY OF YTB323, A CHIMERIC ANTIGEN RECEPTOR (CAR)-T CELL THERAPY MANUFACTURED USING T-CHARGE™, IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA. (23rd June 2022)

17. SAFETY AND ACTIVITY OF THE HIGHLY SPECIFIC BTK INHIBITOR, BGB‐3111 PLUS OBINUTUZUMAB IN PATIENTS (PTS) WITH FOLLICULAR LYMPHOMA (FL) AND CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). (June 2017)

18. THE FIRST‐IN‐CLASS ANTI‐CD47 ANTIBODY HU5F9‐G4 + RITUXIMAB INDUCES DURABLE RESPONSES IN RELAPSED/REFRACTORY DLBCL AND INDOLENT LYMPHOMA: INTERIM PHASE 1B/2 RESULTS. (12th June 2019)